FDA again rejected Capricor’s Duchenne cell therapy, according to an FDA statement accusing the company of “serious data integrity violations” that compromised the study findings. The agency said the issues led to the therapy’s second rejection since 2025, intensifying regulatory scrutiny around the integrity of supporting datasets. For Capricor, the setback delays potential approval and increases the compliance burden needed to repackage the evidence. The company now faces a key question for any resubmission: whether remediation efforts can address the specific data handling and documentation failures cited by the regulator.
Get the Daily Brief